The use of pharmacotherapies for the treatment of generalized anxiety disorder (GAD) has grown sharply, fueled by an increasing prevalence of the disorder and constrained access to nonpharmacologic…
Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the…
Clarivate Epidemiology’s coverage of IgA nephropathy (IgAN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
The drug market for chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria) is dominated by oral medications, including those approved (e.g., first- and second-…
Epilepsy is a heterogeneous condition requiring individualized treatment, especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…
Clarivate Epidemiology’s coverage of hidradenitis suppurativa (HS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Prostate Cancer
Clarivate Epidemiology’s coverage of acute lymphoblastic leukemia (ALL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of Sjogren’s syndrome (SS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of Sjogren’s syndrome (SS) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Sjogren’s syndrome disease patient populations, covering 171…